ICU Medical, Inc. Peer Comparison
Metric | Value | Ranking | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap | $3.9 Billion | 5/12 | COO $17.6B |
HOLX $14.2B |
ATR $9.6B |
MMSI $6.3B |
ICUI $3.9B |
NVST $3.7B |
XRAY $3.6B |
HAE $3.1B |
ATRC $2.0B |
ATRI $809.4M |
ANGO $418.4M |
AKYA $114.5M |
Gross Margin | 35% | 11/12 | ATRC 75% |
COO 67% |
AKYA 62% |
HOLX 57% |
HAE 56% |
ANGO 55% |
NVST 53% |
XRAY 52% |
MMSI 46% |
ATR 39% |
ICUI 35% |
ATRI 32% |
Profit Margin | -6% | 8/12 | HOLX 20% |
COO 12% |
ATR 12% |
HAE 11% |
MMSI 8% |
ATRI 1% |
NVST 1% |
ICUI -6% |
ATRC -7% |
ANGO -15% |
XRAY -52% |
AKYA -56% |
EBITDA margin | 1% | 9/12 | HOLX 34% |
ATR 23% |
MMSI 22% |
COO 19% |
HAE 17% |
NVST 10% |
ATRI 9% |
XRAY 7% |
ICUI 1% |
ATRC -1% |
ANGO -3% |
AKYA -44% |
Quarterly Revenue | $589.1 Million | 6/12 | HOLX $1.0B |
COO $1.0B |
XRAY $951.0M |
ATR $848.1M |
NVST $601.0M |
ICUI $589.1M |
HAE $348.5M |
MMSI $339.8M |
ATRC $115.9M |
ANGO $72.8M |
ATRI $48.8M |
AKYA $18.8M |
Quarterly Earnings | -$33.0 Million | 11/12 | HOLX $201.0M |
COO $117.5M |
ATR $100.9M |
HAE $37.5M |
MMSI $28.4M |
NVST $8.2M |
ATRI $402,000 |
ATRC -$7.9M |
AKYA -$10.5M |
ANGO -$10.7M |
ICUI -$33.0M |
XRAY -$494.0M |
Quarterly Free Cash Flow | $21.6 Million | 7/12 | HOLX $172.5M |
ATR $107.7M |
XRAY $98.0M |
NVST $63.3M |
MMSI $37.4M |
HAE $35.2M |
ICUI $21.6M |
ATRC $16.4M |
ATRI $8.7M |
ANGO $1.7M |
COO -$0 |
AKYA -$0 |
Trailing 4 Quarters Revenue | $2.3 Billion | 6/12 | HOLX $4.0B |
ATR $3.6B |
COO $3.0B |
XRAY $2.9B |
NVST $2.8B |
ICUI $2.3B |
HAE $1.4B |
MMSI $1.3B |
ATRC $447.6M |
ANGO $286.5M |
ATRI $181.6M |
AKYA $86.8M |
Trailing 4 Quarters Earnings | -$111.0 Million | 9/12 | HOLX $1.0B |
COO $1.0B |
XRAY $951.0M |
ATR $848.1M |
NVST $601.0M |
ICUI $589.1M |
HAE $348.5M |
MMSI $339.8M |
ATRC $115.9M |
ANGO $72.8M |
ATRI $48.8M |
AKYA $18.8M |
Quarterly Earnings Growth | -556% | 12/12 | ANGO 63% |
ATR 62% |
COO 39% |
HAE 20% |
AKYA 18% |
ATRC 13% |
MMSI 10% |
HOLX -18% |
NVST -62% |
XRAY -86% |
ATRI -94% |
ICUI -556% |
Annual Earnings Growth | -392% | 10/12 | HOLX 44% |
MMSI 39% |
HAE 23% |
AKYA 23% |
ATR 19% |
COO 15% |
ATRI -26% |
ATRC -59% |
ANGO -307% |
ICUI -392% |
NVST -855% |
XRAY -5900% |
Quarterly Revenue Growth | 6% | 6/12 | HOLX 268% |
ATRC 18% |
ATRI 11% |
COO 10% |
MMSI 8% |
ICUI 6% |
HAE 4% |
ATR 1% |
XRAY 0% |
NVST -5% |
ANGO -8% |
AKYA -25% |
Annual Revenue Growth | 6% | 5/12 | HOLX 30% |
ATRC 12% |
ATRI 11% |
NVST 7% |
ICUI 6% |
HAE 6% |
MMSI 4% |
ATR 2% |
ANGO -9% |
AKYA -9% |
COO -20% |
XRAY -28% |
Cash On Hand | $312.5 Million | 5/12 | HOLX $1.8B |
NVST $991.3M |
MMSI $523.1M |
HAE $320.8M |
ICUI $312.5M |
XRAY $296.0M |
ATR $223.8M |
ATRC $130.3M |
COO $107.6M |
ANGO $54.1M |
AKYA $12.6M |
ATRI $11.5M |
Short Term Debt | $51.0 Million | 4/12 | XRAY $422.0M |
NVST $115.8M |
HOLX $53.4M |
ICUI $51.0M |
COO $33.3M |
MMSI $11.5M |
HAE $5.1M |
AKYA $3.7M |
ATRC $2.7M |
ANGO -$0 |
ATR -$0 |
ATRI -$0 |
Long Term Debt | $1.5 Billion | 3/12 | COO $2.6B |
XRAY $1.9B |
ICUI $1.5B |
NVST $1.3B |
HAE $1.2B |
MMSI $750.5M |
ATR $688.1M |
AKYA $81.2M |
ATRC $61.9M |
HOLX $22.2M |
ANGO $0 |
ATRI $0 |
PE | -1.00 | 7/12 | ATRI 64.46 |
MMSI 52.50 |
COO 44.82 |
ATR 25.71 |
HAE 24.09 |
HOLX 19.07 |
ICUI -1.00 |
XRAY -1.00 |
ANGO -1.00 |
ATRC -1.00 |
NVST -1.00 |
AKYA -1.00 |
PS | 1.68 | 8/12 | COO 5.93 |
MMSI 4.75 |
ATRC 4.46 |
ATRI 4.46 |
HOLX 3.51 |
ATR 2.69 |
HAE 2.28 |
ICUI 1.68 |
ANGO 1.46 |
NVST 1.32 |
AKYA 1.32 |
XRAY 1.25 |
PB | 1.91 | 10/12 | AKYA 8.40 |
MMSI 4.76 |
ATRC 4.29 |
ATR 3.87 |
HAE 3.45 |
ATRI 3.39 |
HOLX 2.97 |
ANGO 2.24 |
COO 2.18 |
ICUI 1.91 |
XRAY 1.46 |
NVST 1.21 |
PC | 12.55 | 5/12 | COO 163.41 |
ATRI 70.62 |
ATR 43.01 |
ATRC 15.31 |
ICUI 12.55 |
XRAY 12.30 |
MMSI 12.05 |
HAE 9.76 |
AKYA 9.12 |
HOLX 7.96 |
ANGO 7.74 |
NVST 3.76 |
Liabilities to Equity | 1.10 | 4/12 | AKYA 8.53 |
HAE 1.79 |
XRAY 1.66 |
ICUI 1.10 |
HOLX 0.83 |
MMSI 0.80 |
ATR 0.79 |
NVST 0.79 |
ANGO 0.56 |
COO 0.52 |
ATRC 0.32 |
ATRI 0.09 |
ROA | -0.03 | 7/12 | HOLX 9% | ATR 8% | HAE 5% | MMSI 5% | ATRI 5% | COO 3% | ICUI -3% | ATRC -6% | XRAY -7% | NVST -24% | AKYA -45% | ANGO -77% |
ROE | -0.05 | 7/12 | HOLX 16% |
ATR 15% |
HAE 14% |
MMSI 9% |
COO 5% |
ATRI 5% |
ICUI -5% |
ATRC -8% |
XRAY -19% |
NVST -44% |
ANGO -120% |
AKYA -425% |
Current Ratio | 1.91 | 9/12 | ATRI 12.12 |
ATRC 4.10 |
COO 2.91 |
ANGO 2.78 |
ATR 2.28 |
NVST 2.26 |
MMSI 2.25 |
HOLX 2.21 |
ICUI 1.91 |
XRAY 1.60 |
HAE 1.56 |
AKYA 1.12 |
Quick Ratio | 0.14 | 9/12 | ATRI 64.46 |
MMSI 52.50 |
COO 44.82 |
ATR 25.71 |
HAE 24.09 |
HOLX 19.07 |
ICUI -1.00 |
XRAY -1.00 |
ANGO -1.00 |
ATRC -1.00 |
NVST -1.00 |
AKYA -1.00 |
Long Term Debt to Equity | 0.75 | 4/12 | AKYA} 5.96 |
HAE} 1.35 |
XRAY} 0.76 |
ICUI} 0.75 |
MMSI} 0.57 |
NVST} 0.42 |
COO} 0.32 |
ATR} 0.28 |
ATRC} 0.13 |
HOLX} 0.00 |
ANGO} 0.00 |
ATRI} 0.00 |
Debt to Equity | 0.78 | 4/12 | AKYA 6.23 |
HAE 1.35 |
XRAY 0.93 |
ICUI 0.78 |
MMSI 0.57 |
NVST 0.46 |
COO 0.32 |
ATR 0.28 |
ATRC 0.13 |
HOLX 0.01 |
ANGO 0.00 |
ATRI 0.00 |
Burn Rate | 2.91 | 6/12 | MMSI 117.73 |
HAE 25.53 |
NVST 13.58 |
ATRC 11.84 |
ANGO 5.04 |
ICUI 2.91 |
AKYA 0.85 |
XRAY 0.44 |
ATR -3.05 |
HOLX -9.54 |
COO -15.03 |
ATRI -28.51 |
Cash to Cap | 0.08 | 6/12 | NVST 0.27 |
HOLX 0.13 |
ANGO 0.13 |
AKYA 0.11 |
HAE 0.10 |
ICUI 0.08 |
XRAY 0.08 |
MMSI 0.08 |
ATRC 0.07 |
ATR 0.02 |
COO 0.01 |
ATRI 0.01 |
CCR | -0.65 | 9/12 | ATRI 21.63 |
NVST 7.72 |
MMSI 1.32 |
ATR 1.07 |
HAE 0.94 |
HOLX 0.86 |
ANGO -0.16 |
XRAY -0.20 |
ICUI -0.65 |
ATRC -2.09 |
COO |
AKYA |
EV to EBITDA | 631.77 | 1/12 | ICUI} 631.77 |
ATRI} 175.38 |
COO} 101.11 |
MMSI} 88.79 |
XRAY} 87.16 |
NVST} 70.63 |
HAE} 68.39 |
ATR} 51.78 |
HOLX} 35.38 |
AKYA} -22.38 |
ANGO} -145.27 |
ATRC} -2059.28 |
EV to Revenue | 2.22 | 8/12 | COO 6.77 |
MMSI 4.93 |
ATRI 4.39 |
ATRC 4.31 |
HOLX 3.08 |
HAE 2.94 |
ATR 2.82 |
ICUI 2.22 |
AKYA 2.15 |
XRAY 1.95 |
NVST 1.48 |
ANGO 1.27 |